Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements

Miller M., Tokgozoglu L., Parhofer K. G., Handelsman Y., Leiter L. A., Landmesser U., ...More

EXPERT REVIEW OF CARDIOVASCULAR THERAPY, vol.20, no.8, pp.609-625, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 20 Issue: 8
  • Publication Date: 2022
  • Doi Number: 10.1080/14779072.2022.2103541
  • Journal Name: EXPERT REVIEW OF CARDIOVASCULAR THERAPY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Chemical Abstracts Core, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.609-625
  • Keywords: Atherosclerotic cardiovascular disease, icosapent ethyl, REDUCE-IT, guidelines, hypertriglyceridemia, PURIFIED EICOSAPENTAENOIC ACID, CORONARY-HEART-DISEASE, TRIGLYCERIDE-RICH LIPOPROTEINS, PRIMARY-PREVENTION, STATIN THERAPY, FATTY-ACIDS, FISH-OIL, HYPERCHOLESTEROLEMIC PATIENTS, CLINICAL ENDOCRINOLOGISTS, SECONDARY PREVENTION
  • Hacettepe University Affiliated: Yes

Abstract

Introduction: REDUCE-IT demonstrated that adding 4 g/day of icosapent ethyl (IPE; purified ethyl ester of eicosapentaenoic acid [EPA]) to statins substantially reduced cardiovascular disease (CVD) events, with few adverse effects. These data prompted numerous leading medical societies across five continents, including the American College of Cardiology, the European Society of Cardiology, and the Japanese Circulation Society, to update their guidelines or scientific/consensus statements to recommend use of IPE for primary and secondary prevention of CVD events.